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Abstract: Prostate cancer (PCa) is the most prevalent cancer, a significant contributor to morbidity and a leading cause of 
cancer-related death in men in Western industrialized countries. In contrast to genetic changes that vary among individual 
cases, somatic epigenetic alterations are early and highly consistent events. Epigenetics encompasses several different 
phenomena, such as DNA methylation, histone modifications, RNA interference, and genomic imprinting. Epigenetic 
processes regulate gene expression and can change malignancy-associated phenotypes such as growth, migration, 
invasion, or angiogenesis. Methylations of certain genes are associated with PCa progression. Compared to normal 
prostate tissues, several hypermethylated genes have also been identified in benign prostate hyperplasia, which suggests a 
role for aberrant methylation in this growth dysfunction. Global and gene-specific DNA methylation could be affected by 
environmental and dietary factors. Among other epigenetic changes, aberrant DNA methylation might have a great 
potential as diagnostic or prognostic marker for PCa and could be tested in tumor tissues and various body fluids (e.g., 
serum, urine). The DNA methylation markers are simple in nature, have high sensitivity, and could be detected either 
quantitatively or qualitatively. Availability of genome-wide screening methodologies also allows the identification of 
epigenetic signatures in high throughput population studies. Unlike irreversible genetic changes, epigenetic alterations are 
reversible and could be used for PCa targeted therapies. 
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1. INTRODUCTION 
  Prostate cancer (PCa) is the most frequently diagnosed 
non-skin malignancy and the third leading cause of cancer-
related death in men in the Western world [1]. PCa is one of 
the most complicated human tumors and, like many other 
malignancies, arises from progressive genetic and epigenetic 
alterations. The field of epigenetics has rapidly evolved and 
influenced research in different biological phenotypes such 
as aging, memory formation, and embryological develo-
pment. Overall, epigenetic defects reported in cancers 
include reactivation of embryonic genes, loss of imprinted 
genes changing inactive and active alleles, dysregulated 
expression of micro-RNAs, increased gene recombination, 
and transcriptional silencing of tumor-suppressor and 
housekeeping genes. Epigenetics encompasses several 
different phenomena, such as DNA methylation, histone 
modifications, RNA interference, and genomic imprinting 
[2]. Epigenetic processes regulate gene expression and can 
change malignancy-associated phenotypes such as growth, 
migration, invasion, or angiogenesis.  
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  Unlike many other genetic changes, epigenetic processes 
are reversible and do not affect DNA sequence or quantity. 
However, they promote genomic instability that might lead 
to oncogenic activation and / or inactivation of tumor 
suppressors. Normal methylation levels of various genes 
preserve cellular homeostasis. Among all recognized 
epigenetic alterations, aberrant DNA methylation (hypo- and 
hypermethylation) is the most important and the best 
characterized change in PCa [3]. Hypermethylated genes in 
PCa include DNA damage repair genes (e.g., glutathione S-
transferase Pi (GSTP1) and the DNA alkyl-repair gene O
6-
methylguanine DNA methyltransferase (MGMT)), hormonal 
response genes (e.g., androgen receptor (AR), estrogen 
receptor (ER)), cell-cycle control genes (e.g., CDKN2A), 
tumor-suppressor genes (e.g., VHL, RB1, APC), apoptosis 
genes (e.g., death-associated protein kinase (DAPK)), and 
invasion and metastasis genes (e.g., Cadherins, CD44, 
TIMPs). In addition, global and gene-specific hypomethyl-
ation have also been associated with PCa. Epigenetic events 
may also play a role in benign prostatic hyperplasia (BPH). 
Epigenetic regulatory mechanisms appear very sensitive to 
external stimuli or influences such as diet and oxidative 
stress. A comprehensive review on epigenetic alterations in 
PCa is beyond the scope of this review. Our intention is to 
provide a synopsis of widely known DNA methylated genes 
and their biological activity and pathways, interaction 
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epigenetic biomarkers for PCa diagnosis and prognosis, and 
epigenetic targets for PCa therapy. Finally, we review a 
number of methods for detection of DNA methylation and 
available data bases and computational analytical tools.  
2. DNA METHYLATION AND REGULATION OF 
GENE EXPRESSION 
  Epigenetic mechanisms such as DNA methylation and 
histone modification play an essential role in many 
molecular and cellular alterations associated with the 
development and progression of prostate cancer [4, 5]. In 
mammalian cells, most of the chromatin exists in a 
condensed, transcriptionally silenced form called hetero-
chromatin. Euchromatin is less condensed and contains most 
of the actively transcribed genes. Histones and DNA are 
chemically modified with epigenetic markers that influence 
the chromatin structure by altering the electrostatic nature of 
the chromatin or by altering the affinity of chromatin binding 
proteins. DNA methylation is usually associated with histone 
deacetylation, chromatin condensation, and gene silencing 
[5-7]. 
  DNA methylation leads to gene-silencing either by 
inhibiting the access of target binding sites to the 
transcriptional activators [8] or by promoting the binding of 
methyl-binding domain proteins, which can mediate 
repression through interaction with histone deacetylases 
(HDACs) that promote chromatin condensation into 
transcriptionally repressive conformations [9, 10]. 
  DNA methylation involves the addition of a methyl 
group to the fifth carbon position of the cytosine pyrimidine 
ring via a methyltransferase. DNA methylation refers to the 
covalent bonding of a methyl group specifically to the 
dinucleotide CpG, which is catalyzed by the family of 
enzymes known as DNA methyltransferases (DNMTs). It is 
thought that DNA methylation alters chromosome structure 
and defines regions for transcriptional regulation. This 
covalent modification of multiple DNA sites by methylation 
is a heritable and reversible epigenetic process, which is 
involved in the regulation of a diverse range of biological 
processes [11-13]. Clusters of CpG sites are dispersed 
around the genome and are referred to as CpG islands, 
stretches of DNA ranging from 0.5 to 5 kb with a guanine-
cytosine (GC) content of at least 50%. These islands are 
found in the promoter region of about 60% of genes, in 
exons and introns, and in repetitive elements. Most CpG 
islands in the promoter regions are unmethylated, whereas 
CpG islands in intronic regions and repetitive sequences are 
heavily methylated, perhaps to help the cell identify regions 
for gene transcription [14]. 
  There are two distinct classes of DNMTs. The first class 
consists of de novo methyltransferases  (DNMT3a and 
DNMT3b) that methylate DNA irrespective of whether the 
template is hemi-methylated or not. These enzymes are 
involved in the establishment of new DNA methylation 
patterns during development. The maintenance DNA 
methyltransferase DNMT1 belongs to the second class of 
enzymes. Disruption of the mouse Dnmt1  gene results in 
genome-wide demethylation and developmental arrest. Thus, 
the role of DNMT1 in propagating parental DNA 
methylation during replication cannot be substituted by other 
DNMTs [15]. Without the DNMTs, the replication 
machinery itself would produce daughter strands that are 
unmethylated and, over time, would lead to passive 
demethylation. 
  Outside of CpG islands, CpG methylation is thought to 
suppress the transcription of transposable elements and 
spurious initiation of transcription elsewhere. DNA 
methylation abnormalities, such as the gain of methylation in 
normally unmethylated promoters or other regulatory regions 
(hypermethylation), contribute to tumorigenesis by 
decreasing the activity of tumor-suppressor genes. Loss of 
methylation in normally methylated repetitive sequences that 
lead to activation of proto-oncogenes and genomic instability 
is evident in almost all human tumor types [16,17]. DNA 
methylation is the best established epigenetic mark that is 
critical for the allele-specific expression of imprinted genes 
[18]. Hypomethylation of specific chromosomal domains has 
been linked to chromosomal instability [19]. Chromosomal 
abnormalities associated with hypomethylation include 
isochromosomes, unbalanced juxtacentromeric translo-
cations, and whole-arm deletions. DNA hypomethylation of 
repetitive elements, retrotransposons, and CpG poor 
promoter regions plays an important role in tumorigenesis 
[20]. Hypomethylation of repetitive sequences and 
retrotransposons are associated with chromosomal 
rearrangements and translocation to other genomic regions, 
thereby promoting genomic instability [21, 22]. 
  CpGs are underrepresented in mammalian genomes and 
occur in only 1% of the genome, lower than the expected 
statistical fraction of 6%. The methyl donor for this reaction 
is supplied by S-Adenosyl Methionine (SAM). This substrate 
is recycled through a folate- and cobalamin-dependent 
pathway. Hypomethylation or loss of methylation can be 
accelerated by altering this regenerative process through a 
deficiency of Vitamin B9 (folate), vitamin B12, or other 
substrates [23]. There are multiple roles for DNA 
methylation in mammals and disruption of this process 
during early development by the inactivating DNMTs is 
lethal [24].  
  DNA methylation also has a putative role in genome 
defense. All cells in culture or organisms in environment 
challenged life are subject to stringent conditions of 
selection, even the cell which has been forced by its innate 
recombination mechanisms to tolerate the genomic insertion 
of foreign DNA can avail itself of an ancient defense 
mechanism against the genetic activity of foreign DNA that 
could carry active genes. Since promoter methylation has 
been identified as part of a mechanism for the long-term 
silencing of genes and DNA segments, the de novo 
methylation of integrated foreign DNA can be contemplated 
as a defense mechanism or at least as an integral part of it 
[25]. 
  Methylation is also involved with genomic organization 
and silencing unneeded genes in differentiated cells. During 
this process, DNA methylation acts as a stable tag on the 
promoter of a gene that recruits methyl-binding proteins 
(MBPs) and other proteins such as HDACs, to form large-
scale heterochromatic structures that silence the associated 
genes. Changes in DNA methylation during cancer 
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  Three types of altered DNA methylation patterns have 
been observed in human tumors: hypomethylation, 
hypermethylation, and loss of imprinting [26]. DNA 
hypomethylation occurs in many tumors, particularly in 
advanced stages, and is generally assumed to be a genome-
wide event [27, 28]. By comparison, DNA hypermethylation 
occurs at specific regulatory sites, such as in the promoter 
regions of tumor-suppressor genes, and thereby decreases the 
expression of individual genes [29-31]. As a consequence, 
hypermethylation may be functionally equivalent to an 
inactivating gene mutation. Loss of imprinting, which refers 
to the loss of differential expression of the parental alleles, is 
often seen in embryonal tumors [32, 33]. While genome-
wide hypomethylation, which could lead to activation of 
previously silenced genes, is seen in some advanced, 
metastatic PCas [28], most studies have emphasized DNA 
hypermethylation as an important mechanism for 
inactivation of key regulatory genes in PCas [27, 34]. For 
example, decreased expression of E-Cadherin, a component 
of the E-Cadherin/catenin cell adhesion complex, is 
associated with poorly differentiated and late-stage PCa and 
is closely linked to the progression of the disease [35]. Since 
the promoter of E-Cadherin is frequently found to be 
hypermethylated in prostate tumors and PCa cell lines and 
can be reversed by demethylation, it is likely that 
hypermethylation accounts for the reduced expression [31]. 
In contrast, hypermethylation is not responsible for the 
observed reduction in PCa of P-Cadherin expression, another 
member of the Cadherin family [36], illustrating the gene 
selectivity of DNA hypermethylation (Fig. 1).  
3. HYPERMETHYLATED GENES IN PROSTATE 
CANCER 
  DNA hypermethylation is the most common and best-
characterized epigenetic abnormality in human malignancies, 
including PCa. Significantly, many of the affected genes 
encode proteins that are involved in critical cellular 
processes and/or have tumor-suppressor activity (Table 1). 
Pathways frequently disrupted by CpG island 
hypermethylation include DNA damage repair, hormonal 
responses, tumor-cell invasion/metastasis, and cell cycle 
control (Fig. 2). For many of these genes, promoter 
hypermethylation is often the primary or only mechanism 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic representation of dietary factors, one-carbon metabolism, methionine cycle in DNA methylation. One-carbon 
metabolism is the best understood pathway of dietary regulation of DNA methylation. Folic acid is converted to dihydroflate (DHF) and then 
to tetrahydrofolate and finally to methylene tetrahydrofolate (MTHF). 5, 10-MTHF is required for the synthesis of nucelic acids, and 5-
MTHF is required for the formation of methionine from homocysteine via  folate- and B12-dependent methionine synthase reaction. 
Methionine adenosyl transferase transfers adenosine to methionine and generates S-adenosylmethionine (SAM), which is the main methyl 
donor. Subsequently, SAM is converted to S-adenosyl homocysteine (SAH), which has high binding affinity to methyltransferases (MTase). 
A dietary supply of vitamins B12, B6, and folic acid via several steps regenerate SAH to SAM. Methylene tetrahydrofolate (MTHF) can 
direct folic acid (FA) to nucleotide synthesis as an important path for DNA synthesis, cell growth, and DNA repair or for conversion of 
homocysteine to methionine. DNA-methyl transferases (MTase) methylates the CpG island which recruits the methyl binding domain 
(MBD) and histone deacetylases (HDACs) to the methylated DNA and leads to histone deacetylation, condensation of chromatin, loss of 
transcription factor binding, and silencing of the gene expression in cancer and other premalignant conditions.  
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underlying functional loss in PCa. Inappropriate silencing of 
these genes can contribute to cancer initiation, progression, 
and metastasis. Some of the hypermethylation occurs in the 
early stages of PCa progression; along the multistep process 
of prostate carcinogenesis; some correlate with pathological 
grade or clinical stages of PCa; some contribute to 
invasiveness, metastasis and androgen independence of PCa 
[37].  
3.1. DNA Damage Repair Genes  
  DNA repair is a correcting mechanism that maintains 
genomic integrity during replication or after DNA damage. 
Cells that are defective in the components of DNA repair 
pathways exhibit higher rates of spontaneous DNA 
mutations, which can lead to cancer [38]. The 
hypermethylation of two genes involved in DNA damage 
repair, the detoxifier gene glutathione S-transferase Pi 
(GSTP1) and the DNA alkyl-repair gene O
6-methylguanine 
DNA methyltransferase (MGMT), has been reported in PCa.  
  Glutathione S-transferase (GST) is a family of enzymes 
involved in the detoxification of xenobiotics and oxygen 
radicals [39]. Human GSTs are classified into distinct 
families; five of which encode cytosolic GSTs, , , , ,  
forms. The product of  gene (GSTP1), which is located on 
11q13, can detoxify environmental electrophilic carcinogens 
and oxidants and might have a genomic care taker role by 
preventing oxidant and electrophilic DNA damage and the 
resulting mutations [40]. GSTP1 expression is detectable in 
Table 1.  Genes Frequently Hypermethylated in Prostate Cancer 
Prostate cancer  Gene Chr
a Role/Function  Hyper 
methylation 
Primary
b Met
c 
Cell 
lines
d 
Ref. 
Glutathione –S-transferase Pi (GSTP1)  11q13  Intracellular detoxification  70% - 100%  +    +  [50] 
Glutathione-S-transferase (GSTM1)  1p13  Intracellular detoxification  58%  +      [178] 
O-6-Methylguanine DNA-
Methyltransferase 
(MGMT) 
10q26  Remove alkyl adducts from 
O
6 -guanine 
76% +    +  [44] 
Retinoic Acid Receptor beta 
(RAR ) 
3p24 Tumor  suppressor  84%  +     [68] 
Androgen Receptor (AR)  Xq12  Hormone regulation  39%  +      [216] 
Estrogen Receptor Alpha (ER) 6q25  Hormone  regulation 90-95%  +     [56] 
Estrogen Receptor beta (ER) 14q23  Hormone  regulation  79-100%  +    [56] 
Ras association domain family 1A 
(RASSF1A) 
3p21  Tumor suppressor:cell 
growth 
53-79%     +  [81] 
Death Associated Protein Kinase 1 
(DAPK1) 
9q34  Regulator of cell growth  36%  +      [46] 
Endothelin Receptor B (ENDRB)  13q22  Tumor suppressor  45-72%  +  +  +  [81] 
E-Cadherin (CDH1)  16q22  Tumor suppressor: invasion 
and metastasis 
61-72% +      [76] 
Cyclin-dependent kinase inhibitor2A/p16 
(CDKN2A/p16) 
9p21 Tumor  suppressor  66%  + +    [217] 
Cyclin-dependent kinase inhibitor1C/p57 
(CDKN1C/p57) 
11p15 Tumor  suppressor  56%     +  [218] 
Cyclin-dependent kinase inhibitor1B/p27 
(CDKN1B/p27) 
12p13 Tumor  suppressor  6%  +      [45] 
Cyclin-dependent kinase inhibitor1A/p21 
(CDKN1A/p21) 
6p21 Tumor  suppressor  6%  +     [45] 
Tissue Inhibitors of Metalloproteinase-2 
(TIMP-2) 
17q25 Tumor  suppressor  78.5%     +  [219] 
aChr: Chromosomal location. 
bPrimary prostate cancers. 
cMets: Metastatic prostate cancers. 
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normal tissues at varying levels in different cell types. 
Notably, a loss or low level of GSTP1 expression has been 
reported in high-grade prostatic intraepithelial neoplasia 
(PIN) and PCa. Methylation of the GSTP1 gene promoter 
has been the most frequently detected epigenetic alteration, 
and occurs in over 90% of cancerous samples and about 70% 
of prostatic intraepithelial neoplasia (PIN) samples [41, 42], 
but is rarely detected in normal prostate or benign prostatic 
hyperplasia (BPH) tissues. It is also detected in a subset of 
proliferative inflammatory atrophy lesions (PIA). At the 
present time, decreased GSTP1 expression is the most 
common epigenetic alteration in PCa.  
  MGMT is a DNA repair protein that removes mutagenic 
and cytotoxic alkyl adducts from genomic DNA. Tumors 
that lack MGMT expression have a higher incidence of point 
mutations in the genes encoding p53 and K-ras, which may 
influence cancer progression. The MGMT promoter contains 
a CpG island that is methylated in many human cancers [43]. 
Over- expression of MGMT reduces the risk of mutations 
after exposure to methylating agents while loss is associated 
with increased sensitivity to methylating agents and 
carcinogenicity. Results from studies evaluating the MGMT 
promoter methylation in PCa have been unequivocal, with 
moderate to high levels of methylation detected in some 
studies [44, 45], but not others [46, 47]. Further work will be 
necessary to resolve this discrepancy.  
3.2. Hormonal Response Genes  
  The prostate is an endocrine gland that responds to sex 
hormones such as androgens, estrogens, and progesterones 
through their specific receptors. These agents bind to 
specific cellular receptors to mediate their physiological 
effects.  
3.2.1. Androgen Receptor 
  Testosterone and 5-dihydrotestosterone are the most 
important male hormones, with actions mediated through the 
androgen receptor (AR), resulting in the development and 
maintenance of the prostate [48]. The AR gene is located on 
chromosome Xq11–12. The 5’ region of the AR gene 
contains a CpG island according to the criteria established by 
Gardiner-Garden and Frommer [49] indicating that it might 
be regulated by DNA methylation. Jarrard et al. [50] 
analyzed the influence of AR promoter methylation on AR 
gene expression in PCa cell lines. Genetic alterations that 
alter the sensitivity of the AR to androgens, including AR 
gene mutations [51] and amplifications [52] without loss of 
AR expression, are thought to play a key role in the 
development of hormone-independent advanced PCa. 
Epigenetic changes have been accounted for alterations in 
the AR expression in 28% of hormone-independent PCa. 
Epigenetic regulation, including CpG methylation and 
histone acetylation, play important roles in the regulation of 
AR [53]; however, the frequency of AR methylation appears 
to be low in PCa [54-56].  
3.2.2. Estrogen Receptors 
  Estrogens, which have been used for the treatment of 
PCa for decades [57], require estrogen receptors (ERs) to 
mediate their activity [58-60]. The prostate expresses two 
types of estrogen receptors: ER (ER1) and ER (ER2) [61]. 
Lost or decreased expression of ER1 and ER2 in PCa has 
been documented [62-65]. The ER1 gene is frequently 
methylated in PCa and methylation status is associated with 
tumor progression [66]. The ER2 promoter contains a typical 
CpG island [67]. Hypermethylation of the ER2 proximal 
promoter in the PCa cell lines and high frequency in human 
PCa has been documented [56, 68, 69]. Methylation of the 
ER1 and ER2 gene promoters is detectable in BPH; 
however, the extent of ER1 and ER2 promoter methylation is 
significantly less in the BPH samples than in prostatic 
tumors, indicating that prostate carcinogenesis induces ER 
gene hypermethylation [66, 69].  
3.2.3. Retinoic Acid Receptors 
  Retinoids, a group of natural and synthetic vitamin A 
analogs, are important factors in modulating cell growth, 
differentiation and apoptosis which have been shown to 
suppress carcinogenesis in vitro and in vivo. The retinoids 
are among the most investigated classes of chemo-preventive 
drugs for PCa. Their effects are primarily mediated through 
two classes of nuclear receptors – retinoic acid receptors 
(RARs) and retinoid X receptors (RXRs). These classes 
belong to the steroid/thyroid hormone – receptor superfamily 
and are composed of three subtypes (, , ) [70]. The RAR 
gene has two different promoters and expresses RNA 
transcripts that undergo alternative splicing [71]. The 
RAR2 promoter contains a CpG island that is aberrantly 
methylated in PCa [72]. In PCa, RAR2 expression is also 
controlled epigenetically, and a high frequency of aberrant 
methylation has been noted in clinical samples [47, 54, 68 
70, 73-77]. RAR 2 gene methylation is a frequent event in 
PCa. In addition, the RAR 2 promoter is methylated in 20% 
of PIN samples, a putative PCa precursor. Therefore, RAR 
2 gene methylation appears to occur early in PCa etiology, 
and is implicated in cancer initiation [46, 72].  
3.3. Cell Cycle Control Genes 
  A distinguishing characteristic of tumor cells is 
uncontrolled growth, which is regulated by the cell cycle 
pathway. Many genes act as checkpoints that regulate the 
cell cycle and if these genes become defective, may lead to 
carcinogenesis and progression of PCa [78].  
  The tumor-suppressor gene p16/CDKN2 is one of the 
cyclin-dependent kinase inhibitors (CDKIs). CDKN2A, a 
key protein in the signaling pathway, can be affected by a 
variety of genetic and epigenetic changes, including 
hypermethylation in PCa. Aberrant CDKI expression is 
observed in many tumor tissues, including the prostate [45, 
79, 80]. Results regarding the frequency of CDKN2A 
promoter methylation are inconsistent in prostate tumors, 
ranging from 3% to 77%; other studies have investigated the 
role of hypermethylated CDKN2A in the carcinogenesis and 
progression of PCa [45, 47, 79-85]. Herman et al. first 
reported that inactivation of CDKN2A by DNA methylation 
in PCa [86]. The CDKN2A gene was frequently methylated 
in tumor tissue (77%). These data support p16 methylation 
as a potential biomarker for early detection of PCa. Other 
CDKIs such as p14, p21, p27 and RB1 are rarely methylated 
in prostate tumors, and thus, are probably not good 
candidates as biomarkers [45]. DNA Methylation and Prostate Cancer  Current Genomics, 2011, Vol. 12, No. 7    491 
  The RAS family of proto-oncogenes plays a key role in 
the signal transduction pathways involved in cellular 
proliferation and survival, interacting with other regulatory 
circuits of cell growth and death. RAS association domain 
family protein 1 isoform A (RASSF1A) is known as a tumor 
suppressor gene. The RASSF1A protein was found to be 
associated with the DNA repair protein and to mediate the 
apoptotic effect of oncogenic Ras [87, 88]. Inactivation of 
RASSF1A may result in dysregulation of DNA repair system 
and the Ras-dependent growth control in cancer cells. The 
RASSF1A gene is silenced by aberrant methylation of the 
promoter in a large fraction of various cancers including 
prostate [89]. In prostate tumors, RASSF1A promoter 
methylation is a common event, occurring in 49% to 99% of 
tumor tissues and it has been shown to be associated with 
aggressive PCa [44, 47, 89]. 
3.4. Tumor-Suppressor Genes 
  Function loss of classic tumor-suppressor genes through 
DNA hypermethylation is not a common event in PCa. For 
instance, methylation of RB1 [90], hMLH1 [91], and VHL 
[30] has been frequently detected in other types of cancer, 
but not in PCa. Methylation inactivation in CDKN2A and 
CDH1 has shown moderate to high prevalence in PCa [82, 
86, 92].  
  The adenomous polyposis coli (APC) gene, located on 
chromosome 5q21-22, is known as tumor-suppressor gene 
that is responsible for Familial Adenomatous Polyposis 
(FAP). FAP is frequently identified in colorectal cancers, but 
not in PCa [93, 94]; however, involvement of APC 
hypermethylation has been described in different studies [44, 
47, 75, 79, 81, 95, 96]. -catenin mutations have been 
detected in various tumors and are relatively rare in PCa 
[94]. However involvement of  - catenin methylation in 
prostatic carcinogenesis has been recently documented [97].  
  Additional genes with putative tumor-suppressor function 
undergoing epigenetic inactivation by hypermethylation in 
PCa include KAI1 (a prostate-specific tumor metastasis 
suppressor gene) [98],  inhibin- ( a  m e m b e r  o f  t h e  
transforming growth factor– family of growth and 
differentiation factors) [99], and DAB2IP, a novel GTPase-
activating protein for modulating the Ras-mediated signaling 
pathway [100].  It is unknown, however, whether 
hypermethylation of these genes plays a role in prostate 
carcinogenesis or has a role as a biomarker for PCa 
diagnosis. 
3.5. Apoptosis Genes 
  Programmed cell death (apoptosis) is a critical process 
for carcinogenesis in human. Typical morphological 
characteristics of apoptosis include damage to the plasma 
membrane, condensation and fragmentation of the nucleus, 
and DNA fragmentation [101]. A major component of the 
apoptosis pathway is the caspase family. However, other 
genes, including death-associated protein kinase (DAPK), 
fragile histidine triad (FHIT), solute carrier family 5A8 
(SLC5A8), vesicular monoamine transporter 2 (SLC18A2), 
and tumor necrosis factor receptor superfamily, member 10C 
(TNFRSF10C) are also involved in this pathway. A 
repressed expression of these genes by hypermethylation in 
the promoter region has been shown for PCa [46, 47, 81, 
102-106]. However, DAPK and FHIT may have a limited 
value due to a persistently low frequency of methylation in 
tumors and normal tissues [46, 47, 81, 101]. SLC5A8, 
SLC18A2, and TNFRSF10C were found to be hyper-
methylated in 50% to 88% of PCa and were significantly 
downregulated in the tumor when compared to normal 
prostate tissues [103-105, 107-109]. It is noteworthy that, the 
expression of SLC18A2 and TNFRSF10C is inversely 
associated with biochemical recurrence after radical 
prostatectomy [110].  
3.6. Invasion and Metastasis Genes 
  Metastasis is an extremely complicated process that 
occurs through a series of sequential steps involving 
invasion, transport, adhesion to distant sites, and outgrowth 
into a secondary organ. Although metastases are the cause of 
90% of human cancer deaths, little is known about the 
genetic and biochemical determinants of metastasis. Cell–
cell adhesion and cell–substrate adhesion are critical to the 
preservation of the normal tissue architecture. These 
phenotypes are regulated by a group of proteins known as 
cell adhesion molecules (CAMs). Cadherins are a large 
family of CAMs that are involved in cell–cell adhesion. 
Disruption of the cell adhesion system can lead to tumor 
infiltration and metastasis [111,112].  
  E-Cadherin (CDH1), an important member of the 
Cadherin family of cell adhesion molecules, is a 
transmembrane glycoprotein whose extracellular domain 
mediates cell-cell adhesion through calcium-dependent 
homophilic interaction [113]. Decreased CDH1 expression is 
observed in many cancers, a significant correlation between 
loss of CDH1 expression and invasion and metastasis has 
been documented. With regard to PCa, correlations between 
decreased CDH1 expression and prognostic factors including 
tumor grade, stage and ploidy, have been reported [114, 
115]. Methylation of the CDH1 promoter region has been 
detected in PCa cell lines [92]. In human prostate tumors, 
expression of CDH1 is strongly reduced and its promoter is 
methylated to varying degrees [44, 74, 92, 116]. The 5’ CpG 
island of CDH1 is densely methylated in PCa cell lines [31].  
  Matrix metalloproteinases (MMPs) are proteolytic 
enzymes that degrade the extracellular matrix and the 
basement membrane. High expressions of these enzymes 
have been associated with tumor growth, invasion, and 
tumor-induced angiogenesis [117]. These pathways are 
controlled by the balance between the levels of the MMPs 
and tissue inhibitors of metalloproteinases (TIMPs) [118]. 
TIMP-1, TIMP-2, and TIMP-3 are widely investigated 
members of this family involved in tumor progression and 
metastasis in a variety of human cancers. TIMP-2 expression 
appears to have a tumor-promoting role in PCa [119]. The 
promoter region of TIMP-3 was found to be methylated in 
97% of prostate tumors [79] and two studies found TIMP-3 
promoter methylation in 37% and 41% of urine sediments 
from PCa patients [84, 102].  
  CD44 is an integral membrane protein that is involved in 
matrix adhesion and signal transduction. CD44 is classified 
as a metastasis suppressor because decreased CD44 
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metastatic state [120]. It has been reported that loss of 
standard CD44 expression in PCa predicts a poor prognosis 
[121, 122]. The methylation of the 5’ CpG island of CD44 is 
associated with transcriptional inactivation in PCa cell lines, 
as detected in metastasis, indicating an important role in the 
progression of PCa [73-76, 123-126].  
  Others tumor metastasis genes — Caveolin-1 (CAV1), 
H-Cadherin (CDH13), EPHA7, and S100A2 are often 
downregulated in prostate tumor tissues when compared to 
adjacent normal tissues due to methylation [47, 74, 76, 81, 
85, 92, 127-134]. Gene-silencing of CAV1 and CDH13 is 
associated with clinical features of PCa progression [132, 
135, 136]. S100A2 methylation was seen in 75% of cases of 
nonmalignant tissues and in 100% of cases of BPH [133].  
4. DNA HYPOMETHYLATION 
  DNA methylation in mammalian genomes is a DNA 
preservation mechanism by which repetitive DNA, (~50% of 
genome’s content), is transcriptionally silenced to prevent 
their expression and function [137].  Demethylation of 
normally methylated DNA, also known as hypomethylation, 
can disrupt such a defense mechanism, leading to structural 
and functional alterations of the genome. 
  There are two types of hypomethylation, global or 
genomic, which refer to an overall decrease of 5-
methylcytosine content in the genome, and localized or gene-
specific hypomethylation, which refers to a decrease in 
cytosine methylation relative to the “normal” methylation 
level. The latter process affects specific regions of the 
genome, such as the promoter regions of proto-oncogenes or 
normally highly methylated sequences, such as repetitive 
sequences and oncogenes [138]. Both global 
hypomethylation and gene-specific hypomethylation have 
been implicated in human cancers (Table 2).  
4.1. Global Hypomethylation 
  Global hypomethylation, relative to the normal situation 
in PCa, has been reported in a few cases [28, 85, 139-143]. 
Subsequently, more sensitive and precise analysis of 
genome-wide hypomethylation has been conducted. LINE-1 
retrotransposon sequences constitute between 5-10% of 
human genome and are strongly methylated in somatic 
tissues [144]. With LINE-1 hypomethylation analysis, the 
frequencies of DNA hypomethylation in PCa are reported to 
be 7-53%, leading to the hypothesis of a relationship 
between LINE- 1 hypomethylation and GSTP1 
hypermethylation, or alterations on chromosome 8 [85, 139, 
140].  
  Genome-wide hypomethylation, which could lead to 
activation of previously silenced genes, is seen in some 
advanced, metastatic PCa [28]. Heparanase degrades heparin 
sulfate and has been implicated in tumor progression. 
Increased heparanase expression in PCa tissue has been 
reported to be caused by promoter hypomethylation with an 
up-regulation of the transcriptional factor, Early Growth 
Factor Response1 (EGFR1) [142]. Cytochrome P450 1B1 
(CYP1B1), a member of the CYP superfamily that is 
overexpressed in PCa, is also regulated by a 
hypomethylation of its promoter/enhancer region [143].  
4.2. Gene-Specific Hypomethylation 
  Genes from cancer cells but not from normal cells are 
substantially hypomethylated [145].  Moreover, when 
compared to adjacent normal tissues, most cancer tissues 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Schematic diagram of involvement of DNA methylation in different cellular processes. DNA methylation is the best known 
epigenetics alteration in prostate cancer. DNA methylation can regulate gene expression and can function in favor of malignancy-associated 
phenotypes such as cellular differentiation, growth, migration and invasion, metastasis, apoptosis, hormonal regulation of steroid receptors, 
and DNA repair. DNA methylation appears to be very sensitive to external stimuli or influences such as diet and oxidative stress. 
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contain two hypomethylated ras oncogenes, c-Ha-ras and c-
Ki-ras  [146]. In the prostate, the Plasminogen Activator 
Urokinase (PLAU) gene is highly expressed in most PCa 
tissues [147] and invasive PCa cell lines [148]. The PLAU 
gene encodes urokinase plasminogen activator, a 
multifunctional protein that can promote tumor invasion and 
metastasis in several malignancies, including PCa. DNA 
methylation may also play a role in the regulation of the 
PLAU gene in PCa, with hypomethylation of the PLAU 
promoter being associated with its increased expression in 
hormone-independent PCa cells, higher invasive capacity in 
vitro, and increased tumorigenesis in vivo. However, in 
normal prostate epithelial cells and in hormone-dependent 
LNCaP cells, the PLAU promoter is methylated, resulting in 
lower expression of the gene [149]. Another hypomethylated 
PCa gene is the Cancer Associated Gene (CAGE), a novel 
cancer/testis antigen gene [150]. Hypomethylation of CAGE, 
which occurs in about 40% of PCa cases, is responsible for 
its exclusive expression in cancer tissues [151].  
5. RACIAL DIFFERENCES AND DNA METHYLA-
TION IN PROSTATE CANCER 
  PCa is associated with racial disparities. In 2007, PCa 
was responsible for 37% of all malignancies in black men in 
the US. The PCa incidence and mortality rate is 
approximately 60% and up to threefold higher, respectively, 
in African American (AA) men than in the Caucasians 
(CAs). This tendency has been validated for more than 20 
years before or after the PSA era [152]. Similar incidence 
and mortality rates have been reported in black men of West 
African ancestry from the Caribbean and South America 
[153]. The underlying reasons for such disproportionate 
ethnic differences in PCa prognosis and mortality are 
unclear. In part, genuine racial differences in cancer genetics 
and biology, sociocultural differences and/or access to health 
care systems are responsible, but these factors do not totally 
explain the higher mortality rate in African Americans with 
PCa. Limited knowledge is available for inter-racial 
differences on gene-specific or genome-wide methylation or 
other epigenetic processes in normal individuals or patients 
with PCa. Kwabi-Addo et al. [154] examined the 
methylation levels of six genes (GSTP1, AR, RAR2, 
SPARC, TIMP3, and NKX2-540), which have been 
previously shown to be hypermethylated in Caucasians with 
PCa or cell lines. They compared matched and PCa tissues 
from AAs and CAs who had comparable Gleason scores. 
They observed significant differences in the methylation 
levels in all genes, except GSTP1, in the AA samples in 
comparison with CA samples [154].  
  This observation is in agreement with work by Woodson 
et al. [155], which also demonstrated an increase but no 
significant difference in GSTP1 methylation in PCa tissues 
and benign prostatic hyperplasia samples from AAs 
compared to CAs. Also, it was demonstrated that NKX2-5 
and TIMPC genes were highly methylated in normal prostate 
tissue samples from AAs compared to CAs and that 
methylation of NKX2-5 increased with age in AAs. Thus, it 
was suggested that NKX2-5 may serve as a marker for PCa 
detection and increased sensitivity for detection PCa in AAs 
since the incidence of PCa increases dramatically with age. 
Although Kwabi-Addo et al. [154] observed the relationship 
between DNA methylation and PCa risk, they did not detect 
any significant association between DNA methylation based 
on race. Therefore, the utilization of these genes as “ethnic-
sensitive” biomarkers for PCa is promising and can be 
further assessed with a larger PCa population size, as noted 
by the authors. 
  In addition to the aforementioned genes, the adhesion and 
signal transduction membrane protein CD44, which is 
associated with the progression of localized cancer to 
metastatic disease, has also been shown to be 
hypermethylated in AAs. Woodson et al. [155] examined the 
methylation of three genes involved in the progression of 
PCa, GSTP1, CD44, and E-Cadherin. As noted earlier, there 
was an increase but no significant difference in GSTP1 
methylation, as well as no difference in the frequency 
between AAs and CAs. While E-Cadherin was not 
hypermethylated at all, hypermethylation of CD44 was 
observed among AAs with higher frequencies compared to 
CAs and correlated with tumor grade but not disease stage. 
Table 2.  Genes Frequently Hypomethylated in Prostate Cancer 
Prostate cancer  Gene Chr
a Role/Function  Hypo  methylation 
Primary
b Mets
c 
Cell 
lines
d 
Ref. # 
Urokinase Plasminogen 
Activator (uPA) 
10q24  Tumor invasion and 
metastasis 
75-96.9% +   +  [220] 
Heparanase (HPSE)  4q21  Tumor invasion and 
metastasis 
8.5 -30%  +    +  [142] 
Cancer/testis Antigen Gene 
(CAGE) 
6p24  Cell cycle control: cellular 
proliferation 
34%     +  [151] 
Cytochrome P4501B1(CYP1B1)  2p21  Hydroxylation of 
estrogens and activation of 
carcinogens 
5 – 17%  +    +  [143] 
aChr: Chromosomal location. 
bPrimary prostate cancers. 
cMets: Metastatic prostate cancer. 
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However, Kito et al. reported a correlation between CD44 
hypermethylation and disease stage in a Japanese men [156]. 
Although it is speculated that CD44 hypermethylation may 
have prognostic implications, its methylation and role in 
racial differences in PCa should continue to be explored in 
larger studies. 
6. HISTONE MODIFICATIONS 
  In eukaryotes, genomic DNA is packaged with histone 
proteins into chromatin, compacting DNA some 10,000-fold. 
Such condensation of DNA provides a considerable obstacle 
to the nuclear machinery that drives processes such as 
replication, transcription or DNA repair. Importantly, the 
structure of chromatin dynamically changes, permitting 
localized decondensation and remodeling that facilitates the 
progress of nuclear machinery.  
  The chromatin structure is regulated by a variety of post-
translational modifications including DNA methylation, 
modification of histones, and ATP-dependent chromatin 
remodeling. Histones can be modified by several post-
translational mechanisms including acetylation, methylation, 
phosphorylation, ubiquitination, sumoylation, or ribosylation 
of distinct amino acids, resulting in either the activation or 
suppression of gene expression [157-161].  
  A complete understanding of the precise molecular 
mechanisms by which the histone tail alterations influence 
DNA-histone interactions remains elusive. There are two 
main hypotheses on how histone modifications can affect 
chromosome function: 1) they may alter the electrostatic 
charge of the histone, resulting in a structural change in the 
histones or their binding to DNA; or 2) these modifications 
are binding sites for protein recognition motifs, such as the 
bromodomains or chromodomains, that recognize acetylated 
lysines or methylated lysines, respectively [162].  
  Enzymes that tightly control the balance of covalent 
histone modifications are histone acetyl transferases (HATs) 
and HDACs as well as histone methyltransferases (HMTs) 
and demethylases (HDM). These enzymes alter the 
configuration of the chromatin and regulate gene expression. 
Acetylation of lysine residues in histone tails by HATs 
unpacks the chromatin structure and renders the DNA 
accessible to transcription factors, thereby facilitating gene 
expression. The effects of HATs are counteracted by 
HDACs, which pack chromatin and repress gene 
transcription. In mammals, there are 18 HDACs which are 
subdivided into four distinct classes based on sequence 
homology to yeast HDACs and functional similarities. Class 
I HDACs (1, 2, 3, and 8) are primarily located in the nucleus 
and are ubiquitously expressed. Class II HDACs are divided 
into two subgroups: IIa HDACs (4, 5, 7, and 9) and IIb 
HDACs (6 and 10), which shuttle between the nucleus and 
cytoplasm and show a tissue-specific expression pattern 
[163, 164]. The NAD+-dependent enzymes of Class III 
HDACs (also named SIRTUINS) comprise seven members 
(SirT1– 7) and are ubiquitously expressed. Although most of 
these enzymes were shown to regulate histone acetylation, 
their distinct biological functions are largely due to the 
deacetylation of non-histone proteins such as transcription 
factors.  
  Overall, post-translational modifications of histones 
create an epigenetic mechanism for the regulation of a 
variety of normal and disease-related processes, including 
cancers. Drugs affecting histone modifications already have 
been developed and have shown promising results in the 
treatment of different tumor types.  
7. INTERACTION BETWEEN DNA METHYLATION 
AND HISTONE MODIFICATION IN PROSTATE 
CANCER  
  The silencing mechanism of DNA methylation is only 
part of a complex set of epigenetic regulatory processes. 
Another epigenetic change that is distinct from and yet 
linked to DNA methylation is the modification state of the 
surrounding histones in which the DNA is packaged. DNA 
and histones are linked functionally to control transcription 
and repair. It has been shown that methylated DNA recruits 
HDAC through methyl-DNA binding proteins (MBPs); 
consequently, DNA methylation/ histone deacetylation cross 
talk has been suggested to influence gene silencing [10, 12, 
165-169].  
  The histone modifications exist in relative balance, 
maintained by competing enzymes that constantly work to 
place and remove the appropriate modifications. The signals 
that control these modifications are complex and can include 
DNA methylation and the binding of other protein co-factors 
[170]. In PCa, a number of in vitro studies provide evidence 
that promoter hypermethylation and histone deacetylation 
interact to maintain chromatin in its inactive state. These 
studies have shown that combined treatment with the histone 
deacetylase inhibitor, Trichostatin A, and demethylating 
agents 5-aza-cytidine or 5-aza-2’- deoxycytidine led to 
reversing epigenetic silencing of several genes. A loss of 
hypermethylation in the promoter and concomitant gene 
activation has been observed for a number of tumor-
suppressor genes in various PCa cell lines.  
  Transcriptional activation of a gene is facilitated by the 
addition of acetyl groups on the N-terminal lysines of 
histones to create an open or noncompact chromatin 
(euchromatin) conformation. The addition of acetyl groups 
on histones, primarily histones H2a, H3 and H4, is catalyzed 
by HATs. Increased HAT activities have myriad effects that 
may alter PCa growth in positive and negative ways. They 
can regulate transcriptional co-regulator proteins that bind to 
steroid receptors. For example, the HATs p300, PCAF and 
Tip60 up-regulate the expression or activation state of the 
AR which leads to an increase in the AR signaling in the 
absence of androgen [171, 172]. HATs also increase IGFBP-
2 and p21 activation in PCa, slowing cell-cycle progression 
[4]; thus, HATs affect a range of cellular processes and as 
such they represent a putative target for therapy.  
8. EPIGENETIC CHANGES AND PROSTATE CAN-
CER DIAGNOSIS, PROGNOSIS, AND TREATMENT 
  Prostate-specific antigen (PSA) is a less than-optimal 
tumor marker and cannot effectively differentiate between 
PCa and other conditions such as prostatitis or BPH. The 
false positive results lead to expensive and invasive critical 
investigations such as transrectal prostate biopsies. This 
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reliable potential epigenetic markers for PCa diagnosis, 
prognosis, and follow up treatment.  
8.1. Epigenetic Diagnostic Markers 
 Epigenetic markers, particularly aberrant DNA 
methylation, have the potential to be useful diagnostic tumor 
markers. Historically, there have been two general strategies 
for detecting DNA methylation changes at specific DNA 
sequences in cancer cells. The older approach exploits the 
use of methylation-sensitive restriction endonucleases, which 
cut recognition sites differently depending on whether 5-
meCpG is present [173, 174]. The second major strategy for 
selective detection of genome sequences carrying 
methylation marks features DNA modification using sodium 
bisulfite, a procedure that promotes cytosine deamination to 
uracil but spares 5meC [175, 176]. Methylation markers 
have several advantages over the mutation-based genetic 
markers. Aberrant DNA methylations are more frequent than 
mutations and can be identified by genome-wide screening 
methodologies. DNA methylation markers potentially could 
be tested in tumor tissues and body fluids (e.g., serum, 
urine). The mthylation markers are simple in nature; with 
high sensitivity, these markers can be detected, either 
quantitatively or qualitatively, by available well-established 
techniques (e.g., PCR).  Furthermore, the incidences of 
aberrant DNA methylation are higher than those of 
mutations and can be discovered by genome wide screening 
procedures [177].  
  One of the best characterized epigenetic markers in PCa 
is  GSTpi,  a gene that is hypermethylated and silenced in 
more than 90% of all PCa [178]. It is specific for PCa, 
although methylation of this gene is also found in 
proliferative inflammatory atrophy in the prostate, a 
histological entity that has been linked to PCa development 
[42]. It has also been reported that a methylation assays 
combined with histological analysis improves the diagnostic 
specificity [179]. Several groups examined body fluids 
containing prostate cells, including serum, urine and semen, 
for the presence of GSTpi  methylation in patients with 
cancer. The GSTpi protein is clearly detectable in the urine 
of patients with PCa [180], especially after prostate biopsy. 
Analysis of prostatic secretions obtained from 100 patients at 
radical prostatectomy demonstrated 74% sensitivity, and a 
positive association between the degree of methylation at 
GSTpi and the extent of the cancer [181]. GSTpi CpG island 
hypermethylation was found in 72% of serum samples from 
patients with PCa [182], and it was found to be a significant 
predictor of PSA recurrence in the cell-free serum of men 
with PCa [183].  
  Methylations of several other genes have been studied in 
PCa diagnosis including, RAR, CD44, E-Cadherin 
(ECAD), RASSF1A, APC and tazarotene-induced gene 1 
(T1G1) [75, 76]. Others studies have reported that the use of 
a panel of methylation markers including GSTP1 improves 
the diagnosis of PCa both in body fluids and tissues. Further 
studies are needed before these markers can be used as 
diagnostic markers in routine clinical practice.  
8.2. Epigenetic Prognostic Markers 
  One study demonstrated that GSTP1 hypermethylation is 
seen in 40% of pre-operative bone marrow aspirate in 
patients with advanced PCa [184]. Caveolin-1 (CAV1), E-
Cadherin (CDH1), H-Cadherin (CDH13), EPHA7, and 
S100A2 are the tumor metastatic genes that are often more 
down-regulated in prostate tumor tissues than in adjacent 
normal tissues due to methylation [47, 74, 76, 81, 84, 85, 
127-134]. Silencing of Gene CAV1, CDH1, and CDH13 is 
associated with clinical features of PCa [132, 135, 136]. 
These data suggest that the methylation status of CAV1 and 
CDH1 is not only a potential biomarker for PCa, but may 
also be a predictive marker of disease outcome [135]. Genes 
such as CD44 and T1G1 may exhibit specific methylation in 
high-risk and metastatic tumors and could be used in 
molecular staging and as predictors of disease progression 
[78]. Prostate cancers with a high Gleason score are 
correlated with a higher degree of methylation of many 
genes, such as RAR, RASSF1A, and GSTP1 [185].  
8.3. Epigenetic Changes as Therapeutic Targets 
  Epigenetic information is heritable, but has plasticity. 
Dynamic erasure and writing of epigenetic information take 
place in specific genes during embryonic development [186]. 
This makes it possible to modify unwanted epigenetic 
changes. So far, several classes of drugs, including inhibitors 
of DNMTs and HDACs, are known to modify epigenetic 
information in a manner that is not specific to genes. 
Currently, there are several drugs that are at varying different 
stages of development. They can be broadly classified in two 
groups: (i) DNMT inhibitors and (ii) HDAC inhibitors. 
Some of the drugs are in both groups.  
8.3.1. DNMT Inhibitors 
  DNMTs, especially DNMT1, play important roles in 
maintaining CpG methylation [182], and their inhibitors are 
known to induce hypomethylation. In particular, an inhibitor 
of DNMT1, 5 aza-C, and 5-aza-20-deoxycytidine (5-azadC; 
Decitabine), are two closely related drugs used 
experimentally to inhibit DNA methylation in vitro and have 
been shown to re-activate numerous methylation-silenced 
genes, such as GSTP1 [183] and RAR2 [72]. 5-aza-C and 
5-aza-dC are cytosine analogues that become incorporated 
into DNA and trap DNMT1 during replication, leading to the 
synthesis of nascent DNA in the absence of DNMT activity, 
resulting in DNA demethylation [187-190]. Myelo-
suppression is a major adverse effect, but the treatment is 
well tolerated. 5-aza-dC has been recently approved by FDA 
for clinical use in certain hematological conditions. Another 
drug in the same group, Zebularine can be administered 
orally or intraperitoneally, but has to be given in high doses; 
however, it is chemically stable and has low toxicity [191].  
  Among the chemicals already in clinical use or in food, 
procainamide, procaine and epigallocatechin-3-gallate 
(EGCG) have also shown demethylating activity [192-194]. 
Considering that some aberrant DNA methylation is present 
in the early stages of carcinogenesis, it is possible that such 
demethylating agents may be useful for cancer prevention. 
MG98 is a phosphorothioate antisense oligodeoxynucleotide, 
and is a specific inhibitor of DNA methyltransferase mRNA; 
this drug is also used for demethylation [177].  
8.3.2. Histone Deacetylase Inhibitors 
  In recent years, it became evident that HDACs are 
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aberrant epigenetic states associated with cancer. Various 
studies in cancer cell lines and tumor tissues revealed 
changes in the acetylation levels and the expression of the 
HDAC enzymes [195]. Increased HDAC activity in prostate 
tumors provides another avenue for therapeutic inhibition. A 
variety of natural products exhibit HDAC-inhibitory activity. 
Commonly used HDAC inhibitors that are being tested 
include trichostatin A (TSA), Suberoylanilide hydroxamic 
acid (SAHA) and valproic acid [5]. These drugs appear in 
vitro to also increase the efficacy of radiation therapy [196] 
and they have anti-angiogenesis function [197]. SAHA, a 
class I HDAC inhibitor, significantly represses the growth of 
LNCaP hormone sensitive prostate tumors in nude mice 
(97% inhibition vs untreated controls) [198]. Trichostatin A 
(TSA), leads to hyperacetylation of histones and cell cycle 
inhibitors, such as p21WAF1 [199]. The class I inhibitor and 
benzamide derivative, MS-275 increases xenograft 
radiosensitivity and inhibits prostate tumor growth .The 
HDACi,  LBH589 targets class IIa HDACs and decreases 
angiogenesis in PC-3 xenograft tumors [200]. Various 
HDAC inhibitors have been developed for therapeutic 
purposes, and tumor cells are known to show higher 
sensitivity than normal cells for unidentified mechanisms. 
HDAC inhibitors are also reported to be effective even in 
non-proliferating tumor cells in vitro [201].  
  The combination of HDAC and DNMT inhibitors has 
synergistic effect in the reactivation of silenced gene [5]. 
Another interesting possibility is the combination of 
epigenetic drugs and conventional anti androgens and 
chemotherapeutic agents. It should be cautioned that the 
epigenetic drugs currently lack gene specificity and some of 
them are associated with significant toxicity. Hence, efforts 
are being made to develop gene specific epigenetic drugs 
[177].  
9. METHODS FOR DETECTION OF DNA METHYLA-
TION 
  A wide range of methods are available to either 
quantitatively or qualitatively to find methylated changes in 
genomic DNA. Based on the type of technique used, several 
major groups of detection methods are described here (Fig. 3 
and Table 3). 
9.1. Bisulfite Sequencing 
  This is the most widely used method to examine the 
methylation status of individual cytosines within any 
amplified portion of a gene [202]. It is based on a simple 
principle; the ability of sodium bisulfite to deaminate un-
methylated cytosine residues into uracil in genomic DNA. 
Following PCR amplification, the uracils will be amplified 
as thymines. Cloning and sequencing of the DNA fragments 
will identify the methylated cytosine in CG-islands. 
9.2. Methylation-Sensitive Restriction Fingerprinting 
(MSRF)  
  In this technique, methylated DNA will be subjected to 
restriction enzymes MseI and/or BstUI digestion followed by 
PCR amplification of DNA [203]. Extracted genomic DNA 
will be digested first by MseI enzyme which recognizes the 
TTAA restriction site, which rarely exists in CG-rich areas. 
Therefore, DNA is cleaved into small pieces with the intact 
CG-regions. Subsequently, a fraction of the MseI-digested 
DNA will undergo a second digestion by a methylation-
resistant restriction enzyme, BstUI. This enzyme is able to 
cut un-methylated CGCG segments of the DNA which exists 
in >80% of CG-rich area. The remaining small undigested 
fragments of DNA of BstUI digested and MseI-only digested 
DNAs will be amplified using random-primer PCR and 
compared.  
9.3. Chromatin Immunoprecipitation on DNA 
Microarray (ChIP-chip) 
  In this method, live cells will be fixed by formaldehyde 
crosslinking. After isolating intact genomic DNA with 
transcription factors, antibodies specific to transcription 
factors of interest will be used to immuoprecipitate the 
chromatin-protein complex of interest. Next, DNA will be 
extracted by reversing crosslinking, purified, and chromatin 
amplicons will be generated by PCR. Amplicons will be 
labeled with Cy5, and Cy3will be used to label the input 
reference amplicons. These labeled probes will be applied on 
a CG array for hybridization and data will be analyzed for 
the specific interaction between a unique gene-specific CpG 
site and a specific transcription factor [204]. 
9.4. Luminometric Methylation Assay for Global DNA 
Methylation Analysis 
  Luminometric methylation assay (LUMA) is based on 
DNA cleavage by a combinations of restriction enzymes, 
EcoRI/MspI or EcoRI/HpaII, which leaves the TTAA 
(EcoRI) and methylation-sensitive CG (HpaII) or 
methylation-resistant  MspI overhangs. Bioluminometric 
polymerase extension will be used to quantify the extent of 
restriction cleavage by Pyrosequencing. Following the DNA 
cleavage, the methylation status will be determined by PCR 
or Southern blotting. The extent of CpG sites methylation 
could be accurately and quickly determined by 
Pyrosequencing, which dispenses labeled nucleotides and 
primers and gel-electrophoresis. LUMA has been used to 
evaluate the level of methylated cytosine of the whole 
genome, more frequently to study specific CG islands, to 
determine the association between changes in methylation 
status, and diseases, and as diagnostic or prognostic markers 
of cancers [205-209].  
9.5. Matrix-Assisted Laser Desorption/Ionization Time-
of-Flight Mass Spectrometry (MALDI-TOF-MS) 
  This is a powerful technique to analyze DNA methyla-
tion [210, 211]. A variety of mass spectrometry approaches 
have been developed to measure DNA methylation levels 
such as rapid screening of single nucleotide polymorphisms 
and quantitative allele studies. In addition, it has been used 
to assess nucleotide digestion and DNA sequencing. It 
involves bisulfite conversion of genomic DNA followed by 
DNA sequencing, which leads to accurate determination of 
the levels of genomic DNA methylation. MALDI-TOF-MS 
can measure the gene-specific or genome-wide content of 
methylated cytosine in a high-throughput manner with the 
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9.6. Illumina Human Methylation 27/450 Beadchip Array 
  Genome-wide promoter methylation could be evaluated 
by Illumina Infinium Human Methylation 27/450 Bead 
array. This analysis was made at the Bioinformatics and 
Expression Analysis core facility at the Karolinska Institute. 
The EZ DNA methylation kit (Zymo Research, Orange, CA) 
could be used for bisulfite conversion of genomic DNA, and 
the remaining assay steps could be performed using 
Illumina-supplied reagents and conditions. The Illumina 
Infinium II Bead Array uses allele-specific annealing to 
either methylation-specific probes or non-methylation probes 
to detect the methylation grade of 27,578 individual CpG 
sites  spread across the promoter regions of 14,495 genes 
[212, 213]. The HumanMethylation450K BeadChip includes 
90% of the content contained on the HumanMethylation27 
BeadChip, is designed in the same 12-sample per array 
format. Its unique feature combines unprecedented quality of 
coverage and study design flexibility in running genome-
scale methylation screens. 
9.7. Methylation Analysis by Denaturing Gradient Gel 
Electrophoresis (DGGE) 
  PCR products of bisulfate reacted different gene 
promoter regions could be analyzed using denaturing 
gradient gel electrophoresis (DGGE). In brief, the PCR 
products are loaded on a 10–70% denaturant gradient gel 
together with a fully methylated control (e.g., in vitro 
methylated DNA) and an unmethylated control (e.g., 
peripheral blood lymphocytes). After electrophoresis, gels 
will be stained in Tris/EDTA buffer containing ethidium 
bromide and photographed under ultraviolet transillumi-
nation. Samples are scored as methylated when bands or 
smears are present on the gels in the area below the band 
corresponding to unmethylated DNA [214, 215].  
10. DNA METHYLATION DATA BASE AND 
COMPUTATIONAL ANALYTIC TOOLS 
  During the last decade, epigenetics emerged as a 
vibrating field in biological sciences and specifically cancer 
research that led to significant amount of experimental data. 
Among all others, DNA methylation is the most investigated 
epigenetic alterations. These developments necessitate the 
creation of multi-task or subject-specific databases and more 
and more high-throughput computational methodologies 
capable of handling the enormous experimental data that 
could be tailored for discovering the most relevant biological 
information. Based on the epigenetic profile and in 
translational settings, this knowledge could be used for risk 
assessment, screening, prognostic or diagnostic 
classification, and the development of novel therapeutic 
strategies toward cancers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Step-by-step approach from the discovery to validation of the CpG methylation. Genomic DNA could be extracted from 
different types of biological specimens. Based on the investigators need methylation study could begin using a variety of methylation 
profiling tools and could be followed by PCR and subcloning into a vector, sequencing, aligning into NCBI-Blast data base. After proper 
identification of the gene or sequence of interest or candidate CpG islands, and designing specific primers, final data validation assays is 
necessary to confirm the relationship between methylation level and gene or protein expression. This will be performed by different methods 
listed in the flow chart. BS, Bisulfite sequencing; MSRF, methylation-sensitive restriction fingerprinting; COBRA, Combined bisulfite 
restriction analysis; MSPCR, methylation-sensitive PCR; DGGE, denaturing gel electrophoresis; LUMA, luminometric methylation assay; 
qRT-PCR, quantitative real-time PCR; WB, western blotting. 
Tissue
Cells Genomic 
DNA
Biological 
fluids Methylation  y
Profiling
Strategy Data 
Validation:
PCR
Subcloning
Si
CpG isaland:
Promoter
E
‐BS
‐MSRF
‐COBRA
Sequencing
NCBI‐Blast
Exon,
etc
‐MSPCR
‐DGGE
‐LUMA
‐qRT‐PCR ‐qRT‐PCR
‐WB498    Current Genomics, 2011, Vol. 12, No. 7  Majumdar et al. 
10.1. Databases for CpG Detection Sites 
  Detection of CG dinucleotides and CpG islands are 
central to DNA-methylation research. Based on cytosine and 
guanine frequencies, the CG dinucleotide occurrence in the 
human genome is considerably less than what is expected for 
all the methylated cytosine in the entire genome. The CpG 
islands are defined based on a few default or most common 
parameters that includes a minimal length of approximately 
200 bp, a CG content of approximately 55%, and the 
observed/expected ratio of 0.6 for CG dinuleotides. Based on 
these and other parameters, several data bases are available 
to identify, plot, and report CpG islands in selected DNA 
fragments, such as CpGReport, NewCpGReport, CpGplot, 
and isochore, which are part of the European Molecular 
Biology Open Software Suite (EMBOSS).  
10.2. Databases for Determination of Transcription and 
Translation Initiation Site 
  Methylation silencing of DNA occurs most frequently in 
CpG islands within the promoter region of genes. 
Additionally, the CG dinuleotides of the first exon and intron 
also have important biological significance in terms of 
alternate splicing, multiple transcripts, and protein isoforms 
and functions. Therefore, determination of the transcription 
start site and translation start site are required for the DNA-
methylation analysis of genes. The functional identity of the 
predicted transcription or translational start site (TSS) could 
be experimentally validated. Several databases provide this 
information including the DataBase of Human Transcription 
Start Sites (DBTSS), Eukaryotic Promoter Database (EPD), 
and Ensembl. DBTSS provides the location of TSS, retrieval 
of promoter sequence, extraction of cDNA sequences 
upstream or downstream to TSS [221]. DBTSS is based on 
400,225 and 580,209 human and mouse full-length cDNA 
sequences and contains exact information on the genomic 
positions of the TSSs and the adjacent promoters for 8,793 
and 6,875 human and mouse genes, respectively. The EPD is 
an annotated non-redundant collection of eukaryotic POL II 
promoters for which the TSS has been experimentally 
determined [222]. Available information on this site is either 
extracted from scientific literature or obtained by in silico 
primer-extension method. Access to promoter sequences is 
provided by pointers to positions in nucleotide sequence 
entries. The annotation part of an entry includes description 
of the initiation site mapping data, cross-references to other 
databases, and bibliographic references. EPD is structured in 
a way that facilitates dynamic extraction of biologically 
meaningful promoter subsets for comparative sequence 
analysis. Ensembl is established as a joint initiative between 
EMBL-EBI and the Wellcome Trust Sanger Institute to 
develop a software system for automatic annotation on 
promoters, TSSs, exonic and intronic positions of the 
eukaryotic genomes in more than 50 species (e.g., human, 
rat, mouse, zebrafish) [223]. 
10.3. Analytical Tools for Experimental Design of DNA 
Methylation 
  Epigenetics research has benefited vastly from molecular 
biology methodologies including PCR, DNA sequencing, 
and restriction enzyme digestion and analysis. Most 
commonly used modified versions of these techniques are 
bisulfite conversion and sequencing, methylation-specific 
PCR, and combined bisulfite restriction analysis (COBRA). 
Table 3.  Available Techniques for Detection of DNA Methylation 
Technique Gene-Specific  or 
Genome-wide 
Sample (g)  Advantage and limitations  Ref. 
Bisulfite Sequencing  Gene-specific 
Applicable to 
genome-wide 
0.2-0.5  Gene-specific sequence, Simple set up, Most economic, 
Prone to false positive data, Needs additional confirmatory 
step, Difficulty in primer design, DNA degradation during 
bisulfite treatment 
[202] 
MSRF Genome-wide  0.1-1.0  Simple set up suitable for novel genes screening,  
Special set up for gel electrophoresis 
[203] 
ChIP-chip  Genome-wide  1.0-10  High-throughput, Not common, Platform- specific  [204] 
LUMA Both  0.2-0.5  High-throughput, Relatively expensive,  
Limited sequence size 
[205-209] 
MALDI-TOF-MS  Gene-specific  0.01-1.0  High-throughput, Mostly for specific genes of interest  [210, 211] 
Illumina Methylation 
Beadchip Array 
Genome-wide 0.2-0.5  High-throughput, High accuracy, Relatively expensive, 
Platform-specific 
[12, 213] 
DGGE Gene-specific  0.5-1.0  Very sensitive to variation in DNA sequence, Simultaneous 
analysis of multiple samples possible, Time-consuming, 
No method for automated analyses currently available 
[214, 215] 
MSRF: Methylation-Sensitive Restriction Fingerprinting. 
ChIP-ChIP: Chromatin Immunoprecipitation on DNA Microarray. 
LUMA: Luminometric methylation assayMALDI-TOF-MS. 
MALDI-TOF-MS: Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry. 
DGGE: Denaturing Gradient Gel Electrophoresis. DNA Methylation and Prostate Cancer  Current Genomics, 2011, Vol. 12, No. 7    499 
DNA treatment with bisulfite leads to deamination of 
unmethylated cytosine residues into uracil. Therefore, 
bisulfite treatment is the introductory to determine the 
overall CpG methylation rate or status of any suspected 
DNA fragment. In silico conversion of DNA fragments is 
made possible by Web-based software such as BiQ Analyzer 
that provides bisulfite conversion in addition to reversed 
sequence and retrieval of the complementary strand [224]. 
Following bisulfite conversion, discrimination between 
methylated and unmethylated cytosine residues could be 
accomplished by designing the methylation-specific or 
bisulfite sequencing primers using software such as 
MethPrimer, MethMarker, or MethBLAST. MethPrimer 
detects CpG-specific parameters and islands and is 
essentially based on the primer3 algorithms for designing 
primers [225, 226]. In addition, MethMarker used as 
epigenetic primer design software can be used for epigenetic 
biomarker optimization and the design of assays such as 
bisulfite single-nucleotide primer extension (SNuPE), 
bisulfite pyrosequencing, MSP, methylation analysis by 
DNA immunoprecipitation (MeDIP)-qPCR. MethBLAST 
software uses a BLAST search on a bisulfite converted 
product of methylated and unmethylated cytosine residues of 
the database sequences. It can identify amplicons in the 
converted genome, and determine the specificity of 
generated MSP or bisulfite sequencing primers. COBRA is a 
DNA-methylation analysis strategy that uses methylation-
sensitive restriction enzymes. Consequently, the length of 
the resulting fragments will be used to determine the 
methylation state and site-specificity [227]. The restriction 
enzyme catalogue of New England Biolab (NEB), NEB 
database REBASE [228] and MethMarker can provide a 
comprehensive list of methylation-sensitive restriction 
enzymes to be used in setting up a COBRA experiment. 
10.4. DNA Methylation Database  
  Several databases provide general or specific information 
for epigenetic research. Methdb is a general purpose 
methylation database listing the results of methylation 
experiments ranging from overall genome methylation status 
to site-specific measurements; it covers several species and a 
wide range of methodologies and sample types for broad and 
general methylation studies [229]. MethprimerDB is a 
database linked with MethDB and contains the published 
primers that could be used as positive control in 
experimental settings [230]. This database contains probe 
and primers to test methylation in techniques such as 
COBRA, bisulfite-PCR-SSCP, bisulfite sequencing, MSP, 
and Ms-SNuPE.  
11. FUTURE CHALLENGES AND CONCLUDING 
REMARKS 
  PCa epigenome is a prototypic catastrophic model of 
epigenetic alterations in tumorigenesis and disease 
progression. Alterations in DNA methylation status in 
tumor-suppressor genes, oncogenes, and other regulatory or 
structural genes are the most frequent epigenetic processes 
identified in PCa. The importance of promoter 
hypermethylation in silencing critical tumor-suppressors 
(e.g.,  APC, RASSF1)  in PCa is well documented. Global 
hypomethylation has been identified in primary and 
metastatic PCa. Genome-wide hypomethylation has been 
associated with high grade and advanced stage tumors. 
Overall, the combination of promoter hypermethylation and 
genome-wide hypomethylation might act favorably in 
prostate carcinogenesis and progression. The epigenome 
offers a number of promising prognostic, diagnostic, and 
therapeutic targets for PCa. However, several obstacles need 
to be addressed. The plasticity of epigenetic processes might 
open therapeutic opportunities, but at the same time the 
reversibility of these processes after treatment is of great 
concern. In addition, non-specific targeting of epigenetic 
process by available drugs might lead to short-term or long-
term undesirable side effects. This could be resolved 
significantly by developing gene-specific sustainable 
demethylation approaches. It is not surprising that the field 
of PCa research has focused on identifying “epigenetic 
signature” that could be used for prevention, early detection, 
progression, or distinction between organ-confined indolent 
and aggressive disease. At least for early detection, aberrant 
promoter methylation appears to be the most promising early 
indicator of PCa. Overall, epigenetics is a fascinating and 
expanding field in modern biology that has turned scientific, 
clinical, and public attention to its practical applications for 
cancer prevention, detection, and therapy.  
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